Starpharma Holdings Limited (SPL)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Starpharma Holdings Limited
Stock Code: SPL
GICS Sub-Industry: Biotechnology
Market Cap ($M): 202
Equiv. Shares (M): 285

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.710 $ 0.000 $ 0.000 $ 0.000 $ 0.710 0 0%

Current Broker Consensus Recommendation more
Recommendation: Buy (1.5)
Recommendation Date: 17th Sep 2014
Brokers Surveyed: 2

Company Overview

Business Description:
Starpharma Holdings Limited (SPL) is a biotechnology company that engages in the development of dendrimer products for pharmaceutical, life science and other applications. SPL's underlying technology is built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. SPL has three core development programs: VivaGel portfolio, drug delivery, and agrochemicals.

Strategy Analysis:
Starpharma Holdings reported a net loss of $1.83m for the half-year ended 31 December 2012. Revenues from ordinary activities were $1.29m, up 24% from last year. Basic and Diluted EPS was (1.0) cent compared to (2.0) cents last year. The net operating cash outflow was $10.24m compared to an outflow of $3.9m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  F -8.5 -2.7 -- -26.2 0.0 0.0 0.0
2013  F -8.5 -2.9 -- -24.2 0.0 0.0 0.0
2012  A -14.5 -5.4 -- -25.0 -- -- 0.0
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $240 M -- 6.3247 0.3032 74.6753 10.1950 7.8231 0.00 0.00 0.00
CSL (CSL) $34,348 M 0.0899 0.1803 0.1256 25.3334 21.4633 19.0678 1.66 1.97 2.16
Mesoblast (MSB) $1,579 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $202 M -- -- -0.9512 -- 8.6691 177.5000 0.00 0.00 0.00
Sirtex Medical (SRX) $1,274 M 0.2906 0.5107 0.3715 54.6005 36.1436 26.3527 0.00 0.80 1.33

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
SPL 2.86 -- 6.14 -- 710.0
Market 0.94 15.6 1.28 1.74 1.56
Sector 0.68 22.0 3.21 1.35 8.35

Name Position Start Date
Dr Jacinth (Jackie) K Fairley Chief Executive Officer,Executive Director 01 July 2006
Dr Peter J Jenkins Non-Executive Deputy Chairman,Non-Executive Director 13 May 1997
Ms Zita Peach Non-Executive Director 01 October 2011
Mr Peter Turvey Non-Executive Director 19 March 2012
Mr Richard A Hazelton Non-Executive Director 01 December 2006
Mr Robert Bain Thomas Non-Executive Director,Non-Executive Chairman 04 December 2013

Name Position
N J Baade Chief Financial Officer
Nigel Baade Chief Financial Officer,Company Secretary
C P Barrett VP, Business Development
J R Paull VP, Development and Regulatory Affairs
D J Owen VP, Research

Substantial Shareholders
Holding Name
34,174,302 (12.04%) M&G Investment Funds
36,614,463 (12.90%) Acorn Capital Limited
14,406,827 (5.08%) The Dow Chemical Company
35,194,434 (12.40%) Allan Gray Australia Pty Ltd

Calendar of Events
Date Event
12 August 2015 Report (Annual)
12 August 2015 Report (Prelim)
23 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Active Investing and Trading

An educational booklet with information on how analysis and risk management can enhance your share investments.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links